Inclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors

By sjmartinez • July 4, 2023

Luther VP, Barsoumian AE, Konold VJL, Vijayan T, Balba G, Benson C, Blackburn B, Cariello P, Perloff S, Razonable R, Acharya K, Azar MM, Bhanot N, Blyth D, Butt S, Casanas B, Chow B, Cleveland K, Cutrell JB, Doshi S, Finkel D, Graber CJ, Hazra A, Hochberg NS, James SH, Kaltsas A, Kodiyanplakkal RPL, Lee M, Marcos L, Mena Lora AJ, Moore CC, Nnedu O, Osorio G, Paras ML, Reece R, Salas NM, Sanasi-Bhola K, Schultz S, Serpa JA, Shnekendorf R, Weisenberg S, Wooten D, Zuckerman RA, Melia M, Chirch LM. Inclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors. Open Forum Infect Dis. 2023 May 27;10(6):ofad289. doi: 10.1093/ofid/ofad289. PMID: 37397270; PMCID: PMC10313091.

Tags: Diversity, equity, Inclusion, Infectious Diseases, infectious diseases fellowship, medical education, Publications, Veterans Administration

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]